IBA Molecular
Curium Pharma (formerly IBA Molecular) is a global developer, manufacturer, and distributor of radiopharmaceutical products for nuclear medicine, supplying SPECT and PET imaging agents and therapeutic radiopharmaceuticals to hospitals and clinics across 70+ countries.
- Company typePrivate
- Founded2017
- HeadquartersSterling, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What IBA Molecular does
IBA Molecular is the historical entity that, in 2017, was combined with Mallinckrodt Nuclear Medicine to form Curium Pharma (operating under the corporate parent Curium Bidco sarl in Luxembourg, owned by private equity firm CapVest). The combined business develops, manufactures, and distributes radiopharmaceutical products used in nuclear medicine diagnostics and therapy, including SPECT and PET imaging agents and therapeutic radiopharmaceuticals (with a 30-year track record serving the neuroendocrine tumor community). Operationally, Curium runs four manufacturing sites, a dedicated molybdenum-99 processing plant, more than 45 radiopharmacies, and a portfolio of 50+ products, supplying approximately 6,000 customers across more than 70 countries and reaching roughly 15 million patients annually with a workforce of over 5,000 employees.
The business model is B2B pharmaceutical supply: the company manufactures and distributes short half-life radioactive products through its own manufacturing footprint and licensed radiopharmacy network to hospitals, imaging centers, and clinics, with regional sales, customer service, and distribution entities in the US, Canada, and across Europe (France, Germany, Spain, Italy, the UK, the Netherlands, Sweden, Norway, Denmark, Finland, Belgium, Austria, Ireland, Czech Republic), as well as growth markets including Turkey, India, Malaysia, and Mexico. Pricing is not publicly disclosed and follows enterprise pharmaceutical contract norms rather than published list pricing. Curium is headquartered in Boston (North America) and Paris (Europe), led by CEO Renaud Dehareng, and in November 2025 underwent a CapVest recapitalization described as the largest transaction in nuclear medicine globally, followed by a June 2026 announcement of more than €32 million in strategic investment at its Saclay, France site.
IBA Molecular firmographics
Firmographics- Name
- IBA Molecular
- Legal name
- Curium Pharma
- Website
- https://ibamolecular.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Curium Pharma (formerly IBA Molecular) is a global developer, manufacturer, and distributor of radiopharmaceutical products for nuclear medicine, supplying SPECT and PET imaging agents and therapeutic radiopharmaceuticals to hospitals and clinics across 70+ countries.
- Ownership category
- akta.pro rank
IBA Molecular industry classification
Industry- Product category
- Radiopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)
- akta.pro secondary industries
- Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Radiopharmaceutical & Nuclear Medicine Distributors (HLAIAJAI)
Keywords
Where IBA Molecular is headquartered
LocationHeadquarters
- HQ city
- Sterling
- HQ country
- United States
- HQ region
- North America
Markets served
IBA Molecular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales
IBA Molecular product offering
Product offeringCore offering
IBA Molecular (now operating as Curium Pharma) develops, manufactures, and distributes radiopharmaceutical products and supporting services used in nuclear medicine diagnostics and therapy. The company supplies a portfolio of more than 50 nuclear medicine products and operates radiopharmacies and manufacturing sites serving hospitals, clinics, and imaging centers across more than 70 countries.
Differentiator
Problem solved
Functional benefit
Brands
- ARGOS: Nuclear medicine product brand referenced in company locations
- Curium PET France
Products and services
- ARGOS Nuclear medicine product brand referenced across Curium company locations, indicating it is part of the company's radiopharmaceutical product portfolio sold to healthcare providers.
- Curium PET France radiopharmaceutical products PET radiopharmaceutical products distributed by Curium PET France to nuclear medicine customers in France for diagnostic imaging applications.
- European nuclear medicine product portfolio
Companies that use IBA Molecular
Customer profileIdeal customer profiles1 record
IBA Molecular technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
IBA Molecular partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
IBA Molecular competitors and assessment
Company assessmentBroad incumbents
- GE HealthCare: GE HealthCare is a broad incumbent with a significant nuclear medicine and molecular imaging portfolio spanning equipment, contrast agents, and radiopharmaceuticals. While much larger and more diversified than Curium, it competes directly in the nuclear medicine space.
- Novartis (Radioligand Therapy): Novartis is a broad incumbent that has invested heavily in radioligand therapy with Lutathera and Pluvicto, competing with Curium's NET franchise. While Novartis is much larger and a pharmaceutical major, its radiopharmaceutical division directly targets the same NET patient population.
- Bayer (Radiology): Bayer operates a significant radiology business including CT and MRI contrast agents and is expanding into radiopharmaceuticals through acquisitions. It is a broad incumbent competitor in the imaging pharmaceuticals space.
Direct peers
- PETNET Solutions (Siemens Healthineers): PETNET Solutions, part of Siemens Healthineers, operates a global network of PET radiopharmacies producing and distributing FDG and other PET tracers. It directly competes with Curium's 45+ radiopharmacy network in the PET distribution space.
- Lantheus Holdings: Lantheus is a direct peer as a leading radiopharmaceutical-focused company developing, manufacturing, and commercializing diagnostic imaging agents and therapeutic radiopharmaceuticals. Both companies serve similar hospital and imaging center customers with overlapping SPECT and PET products.
- Cardinal Health Nuclear Pharmacy Services: Cardinal Health operates one of the largest radiopharmacy networks in the United States, distributing nuclear medicine products to hospitals and clinics. It directly competes with Curium's North American radiopharmacy operations.
- Bracco Imaging: Bracco Imaging is a global leader in diagnostic imaging agents and operates in the radiopharmaceutical and contrast media space. The company competes with Curium in the development and distribution of imaging pharmaceuticals across similar customer segments.
Emerging players
- Telix Pharmaceuticals: Telix Pharmaceuticals is an emerging radiopharmaceutical company developing diagnostic and therapeutic agents, particularly in oncology and rare diseases. It represents a smaller but rapidly growing competitor targeting overlapping clinical indications.
Market position
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
IBA Molecular social profiles
Digital presenceIBA Molecular financial estimates
Financial estimateRevenue estimate
Valuation estimate
IBA Molecular leadership team
Management profileNumber of profiles
Profiles1 record
IBA Molecular subsidiaries and ownership
Company hierarchySubsidiaries6 records
IBA Molecular funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IBA Molecular M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IBA Molecular
What does IBA Molecular do?
IBA Molecular (now operating as Curium Pharma) develops, manufactures, and distributes radiopharmaceutical products and supporting services used in nuclear medicine diagnostics and therapy. The company supplies a portfolio of more than 50 nuclear medicine products and operates radiopharmacies and manufacturing sites serving hospitals, clinics, and imaging centers across more than 70 countries.
Is IBA Molecular a public or private company?
IBA Molecular is a private company. It is classified as private equity controlled and is currently operating.
When was IBA Molecular founded?
IBA Molecular was founded in 2017. It employs 501 to 1,000 people.
Where is IBA Molecular based?
IBA Molecular is headquartered in Sterling, United States, in the North America region.
Who are IBA Molecular's main competitors?
Broad incumbents on record are GE HealthCare, Novartis (Radioligand Therapy) and Bayer (Radiology). Direct peers are PETNET Solutions (Siemens Healthineers), Lantheus Holdings, Cardinal Health Nuclear Pharmacy Services and Bracco Imaging. Telix Pharmaceuticals is listed as an emerging player.
Does IBA Molecular have an API?
No public API is recorded for IBA Molecular.
What industry is IBA Molecular in?
IBA Molecular's product category is Radiopharmaceuticals. Its primary akta.pro industry code is EUAKAIAC, Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC), with a secondary code of HLAIAGAE, Radiopharmacy Compounding & Dispensing (Hospital/Commercial). Its NAICS code is 3254 and its SIC code is 2834.